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Bacteriophage MooMoo is a temperate phage that was isolated and propagated on
Mycobacterium smegmatis (M. smeg). It typically produces turbid plaques, however
spontaneous clear plaque mutants can be readily isolated. Both turbid (MooMoo-T) and
clear plaque (MooMoo-C) formers can establish stable lysogens, but the parental turbid
plaque forming phage has a higher lysogenic frequency. The phage repressor protein
typically plays the central role in regulating the lysis/lysogeny decision. Therefore, we
expected that the mutation responsible for the clear plaque phenotype would be located in
the repressor gene. Remarkably, whole genome sequencing detected a single base pair
mutation in the minor tail protein gene (gp19). The regulatory role of the repressor
protein could not be excluded considering it was unclear how the mutation in gp19 was
leading to the altered plaque phenotype.

To locate the phage repressor, we used

bioinformatics to identify several candidate genes with helix-turn-helix and DNA binding
motifs (gp42, gp43 and gp44). We also cloned the parental and mutant gp19 genes.
Each candidate gene was cloned into a shuttle vector. The clones of gp43, gp44 and both
derivatives of gp19 did not prevent MooMoo growth, whereas the clones of gp42
inhibited phage growth. Based on these results, we concluded that gp42 is the phage
repressor for MooMoo.
To determine if the presence of gp19 alters lysogenic frequency, lysogeny assays
of wild-type (WT) and mutant gp19 clones were evaluated. Compared to the MooMoo-C
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lysate, the cloned copy of the mutant gp19 showed a slight increase in lysogeny
efficiency. The lysogeny frequencies on strains that carry cloned copies of gp19 (WT or
mutant) were similar to those obtained on strains that lacked the plasmids. From these
results, we concluded, the presence of either parental or mutant gp19 clones does not
affect the lysogeny frequency.
To determine if host cell physiology was affected by lysogeny, carbon, nitrogen,
phosphorus and sulfur utilization resources were screened using high-throughput
phenotypic microarrays. From these results, we concluded the presence of the WT or
mutant prophage had no significant effect on the utilization of the resources tested.

xi

INTRODUCTION

Bacteriophages (phages) are viral parasites that infect bacterial hosts to produce
new progeny (1, 2, 3). The phage population represents the microbial “dark matter” that
vastly outnumbers any entity on Earth (6, 53). To astronomers and physicists, 85 – 95%
of the universe is composed of dark matter – an invisible mass/energy that has yet to be
directly measured despite its enormity and influences on the evolution of the universe
(74). Analogous to the dark matter of the universe, the phage population is vast and
poorly understood (53). Phages are restricted by the availability of their hosts within an
environment, yet each phage population is a rich source of genetic variation (2). Both
bacteria and their phages drive reciprocal changes within each other in an evolutionary
arms race, as bacteria frequently evolve mechanisms to prevent phage infection (i.e.
CRISPER/Cas systems) and phages relentlessly counter-evolve to infect their hosts (2, 3,
4, 5, 7, 54, 55). Despite co-evolving with their hosts for millions of years, phages were
only discovered a little over a century ago. The first documented accounts of potential
phage activity were made in 1896, by Ernest Hankin’s study on the river waters in India.
Hankin described how the Ganges and Jumna river waters of India contained a filterable
and heat-instable substance capable of killing the bacteria Vibrio cholera (10). However,
Hankin’s evidence was difficult to duplicate and several in the scientific community
doubted his results (10). One of the scientists who discredited Hankin’s research was
Felix d’Herelle (10). Felix d’Herelle was in Mexico, in 1910, assessing diseased locusts
when he first came across clear spots on plates covered with a lawn of bacteria (9, 57).
When d’Herelle swabbed the spots onto a slide and checked under a light microscope,
nothing was seen (56). He hypothesized an unknown factor caused the spontaneous lysis
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of the bacterial cells that created the clear spots (9). After five years of investigating the
locusts, he was called to aid in treating the outbreak of dysentery affecting the French
soldiers stationed near Paris (9, 56). His work with human dysentery was invaluable, but
most infamous was his naming of the filterable bacterial antagonist, the bacteriophage (9,
56, 57).

Felix d’Herelle’s research on bacteriophages, in 1917, was not without

competition. Frederick Twort was a middle class Englishman researching the metabolic
requirements of microbes (9, 57).

In 1915, Twort described an unusual glassy

appearance of several micrococcus colonies (57). He later ascribed that the glassy
transformation occurred by a replicating, filterable and infectious material, but his work
was terminated from a lack of funding and his subsequent enrollment into the Royal
Army Medical Corps (9, 14, 57, 59). In 1921, Twort’s work was finally recognized
eventually resulting in the scientific community acknowledging him as a co-discoverer of
bacteriophages (57).
While working with human dysentery, d’Herelle recognized that bacteriophages
could be used therapeutically to destroy bacterial pathogens. He was able to generate
data that supported his hypothesis by successfully treating multiple cases of enteric
diseases around the world with bacteriophages (9, 14, 56, 58). Enteric disorders were
prevalent among developed and under developed countries as a result of poor sanitary
practices, improper water and waste management measures, along with, inadequate
treatment plans and limited access to medical care (15). Though d’Herelle introduced
and developed phage therapy, the first documented results of successful treatment of a
disease with phages came from Belgium where phages alleviated Staphylococcal skin
infections (14, 59).

Shortly thereafter, d’Herelle’s lab, known later as the L’Oréal
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Company, produced large volumes of five phage therapeutics and marketed them as
being effective against multiple bacterial infections (14). The Eli Lilly Company, in the
United States, began to mass-produce multiple phage therapeutics, which were targeted
against a range of ailments, such as vaginitis, abscesses and upper respiratory infections
(14). Unfortunately the promise of phage therapy never materialized thanks to poor
marketing tactics, limited understanding of phage biology, inefficient phage preparations
and reports of side effects (9, 14, 59). In addition, the discovery of antibiotics provided
the new miracle cure, as these drugs were relatively inexpensive to produce, specific
towards a range of bacteria and lacked the negative side effects sometimes observed with
phage injections (11, 12). Companies, like Eli Lilly, that previously produced phage
therapies, re-directed their attention to manufacturing antibiotics and phage therapy
disappeared in the Western world (11).

As antibiotic production increased, the

incidences of enteric diseases similar to those d’Herelle treated, were nearly eradicated in
the US (15). However, respiratory illnesses proved to more difficult to diagnosis and
treat. For example, the disease known as consumption (tuberculosis) or the “white death”
was spreading within the population (15, 16).
Although Robert Koch had described Mycobacterium tuberculosis (M.
tuberculosis) as the causative agent of consumption in 1895, early treatments were highly
toxic and proved ineffective (15).

Antibiotics were initially successful against

tuberculosis (TB), however antibiotic resistance occurred almost immediately (38). By
mid-1960’s, US federal programs were established to control the spread of TB (15, 16).
Unfortunately, TB was not localized to the US and according the World Health
Organization (WHO), TB is now a pandemic with nearly one-third of the world’s
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population infected (60). Even more alarming, strains of multi-drug resistant (MDR) and
extensively drug resistant (XDR) TB are increasing, rejuvenating the therapeutic need for
phages once more (5, 13, 18, 38, 60).
M. tuberculosis is exquisitely adapted as a human pathogen owing much of its
success having complex cell wall and envelope structures that allow the microbe to
manipulate host immune responses (8, 61, 62, 63). Evidence of TB infections has been
discovered in Egyptian mummies dating back over 4,000 years ago and descriptions of
TB-like symptoms were even noted by Hippocrates (38, 61, 83, 84).

Studying M.

tuberculosis in the laboratory has been difficult and time consuming due to its slow
growth rate (13).
In the late 1930’s, researchers bypassed the prolonged cultivation time of M.
tuberculosis in favor of the “fast growing” relative Mycobacterium smegmatis (M. smeg)
as they share numerous genetic, metabolic and physiological features (13, 19, 20, 39).
Since then, M. smeg has been used as a surrogate for M. tuberculosis to enrich for
mycobacteriophages. After the isolation of the first mycobacteriophages, the decades of
studies that followed, provided crucial information on multiple viral and host aspects,
such as phage morphology, infection mechanisms, lysogenic conversion and alterations
to metabolic functions (13, 17, 21, 22, 23, 24). In 1993, the whole genome of L5 became
the first mycobacteriophage to be sequenced. Subsequent studies on L5 have allowed
scientists to uncover a plethora of gene expression processes involved in the phage life
cycle and lysogeny (64, 65). The research henceforth describes the discovery and
characterization of a clear plaque mutant, along with the in depth analysis on the
properties the mycobacteriophage MooMoo.
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Phage Properties and Morphology
Unlike systematics for living organisms, viruses are sorted by morphological
structures, nucleic composition and method of replication (29). Tailed phages, like those
infecting M. smeg, belong to the Caudovirales group which share a general icosahedral
capsid architecture that encases the genomic double-stranded (ds) DNA (29, 30; Figure
1). Capsids vary in size depending on the total length of the genome, however some
capsids can have an unusual architecture forming unique prolate heads (13, 25, 26, 66).
Prolate capsids are uncommon in mycobacteriophages, yet as Figure 2 illustrates,
mycobacteriophage MooMoo has a prolate head measuring roughly 112 nanometers (nm)
long (13, 17). Phage tails also vary considerably in length and morphology, especially
within mycobacteriophages. The International Committee of Taxonomy of Viruses
(ICTV) determined that tailed phages exhibit three morphotypes – Myoviridae,
Siphoviridae or Podoviridae (13, 21, 27, 71). Mycobacteriophage tails have only two
configurations – Myoviridae and Siphoviridae – contractile or flexible non-contractile,
respectively (13, 17). MooMoo has a Siphoviridae tail measuring approximately 225 nm
in length (Figure 2).

Phage tails mediate the recognition and binding to host cell

receptors, thus they determine host specificity (17, 25, 27, 28). Since these interactions
are critical for the first step in the phage infection process, mutations in specific tail
proteins can often extend host ranges (5).
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Figure 1. General architecture of a tailed bacteriophage.
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Figure 2. Electron micrograph of mycobacteriophage MooMoo. Image shows the
prolate capsid and siphoviridae morphology.
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Mycobacteriophage Genome Clusters
Mycobacteriophages are organized into clusters (Clusters A – Z, AA – AC) based
on genetic similarities (6; Figure 3). Each cluster is further divided into subclusters
demonstrating genetic heterogeneity even among related phage genomes. Phages with no
appreciable homology with any particular cluster are called singletons (6). As Figure 3
shows, MooMoo is a singleton.
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Figure 3. SplitsTree phylogeny of sequenced mycobacteriophages (6). Colored circles
represent clusters, while singletons are labeled (MooMoo, Patience, Muddy, Wildcat,
Sparky, Dori, and Gaia). Electron micrographs illustrate the morphotypes in Corndog
(Cluster O), MooMoo (singleton) and Mozy (Cluster F).
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Phage Life Cycles – Part I (Lytic v. Lysogenic: The Lambda Paradigm)
The lytic cycle was named for the multi-step phage infection process culminating
in cell death upon release of new viral progeny. The infection process begins with
recognition and attachment to host cell surface receptors by the phage tail.

In

conjunction with attachment, tails contain enzymatic activity to degrade the cell wall and
provide a tunnel for the phage genome to enter into the host cell cytoplasm (17). Once
inside the cell, the phage DNA circularizes and the bacterial biosynthetic machinery is
commandeered to transcribe/translate early phage genes. Expression of early phage
genes for DNA replication results in multiple copies of the phage genome being
generated. As phage DNA is replicating, the capsid and tail structural proteins are then
mass-produced. New virions are self-assembled and the phage genome is packaged
inside the capsid (32). The host cell fills with mature virions, while phage encoded lysins
degrade the cell wall of the host (8, 33). The disruption of the cell wall, along with the
formation of channels through the cell membrane by the phage holin proteins, leads to
cell lysis and release of newly formed phages (Figure 4). Lytic phages are those that
strictly enter the lytic cycle and form clear plaques on a lawn of their host.
Temperate phages can enter the lysogenic life cycle as an alternative infection
strategy. Phages that enter the lysogenic pathway do not immediately lyse the host cell.
Some temperate phages integrate their entire genome into the bacterial chromosome after
entering the host cell cytoplasm (Figure 4).

However, before the phage genome

integrates, lytic genes are silenced by the expression of the phage-encoded repressor
protein. Integration is favored by increased levels of Integrase (int), expressed from the
PI promoter.
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Integration events occur between the two genomes at specific homologous
attachment sites, one on the phage genome (attP) and the other on the bacterial
chromosome (attB). Phage integration proteins and host derived integration host factors
(IHF) bind to the attP site and mediate site-specific recombination with the attB site. The
outcome is that the phage DNA integrates to become a part of the host chromosome (35).
The repressor protein continues to be expressed to maintain the lysogenic state. The
integrated phage genome is referred to as a prophage. During host cell division, the
prophage is replicated along with the host chromosome allowing the temperate phage to
by-pass the infection process with each daughter host cell inheriting a copy of the
prophage (Figure 4). Bacterial hosts with integrated phage genomes are called lysogens
and these cells exhibit immunity towards super-infection by the same phage. Prophages
can spontaneously excise from their host chromosome and enter the lytic cycle, and
prophage excision can also be induced by events such as DNA damage.
The archetype for switching between the lysogenic and lytic life cycles is best
represented by the coliphage Lambda. The repressor protein is the central regulatory
factor for maintaining lysogeny. When the repressor is bound to its DNA recognition
sites (operators), lysogeny is promoted and maintained (Figure 5A). When the repressor
is not bound, Lambda enters the lytic cycle (Figure 5B).
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Figure 4. Illustration of lytic and lysogenic life cycles. Lytic events are depicted by the
red arrows. Lysogenic events are shown as two phases – integrated prophage (green
arrow) and excised prophage (blue dotted arrow).
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Figure 5A-B. Lytic/Lysogenic regulation of Lambda. Both A and B are simplified
schematics of the PR promoter based off the detailed information provided in “A Genetic
Switch” (75). Sites 1 – 3 represent the DNA binding (operator) sites. A) Repressor
bound to DNA promotes the lysogenic cycle and maintains lysogeny. B) No repressor
bound to DNA allows the expression of the lytic cycle genes.
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Phage Life Cycles – Part II (Integration of Mycobacteriophage BPs)
Mycobacteriophage BPs provides an interesting alternate example of establishing
and maintaining lysogeny compared to the Lambda paradigm described above. After
injection of the phage DNA into the host cell’s cytoplasm, two intergenic promoters are
activated. The early lytic promoter, PR, synthesizes a Cro-like protein, while the more
active repressor promoter, Prep, upregulates expression of the repressor and integrase
genes (13). The initial increase of Integrase (Int) proteins stimulates integration between
the phage attachment (attP) site and bacterial chromosome (attB) site. Unlike Lambda,
the attP is located in the open reading frame (ORF) of the repressor gene, where sitespecific recombination creates a truncated repressor expressed from the Prep promoter
(40, 44, 70).

After recombination, the integration gene is separated from the Prep

promoter and residual Int proteins are degraded by host proteases.

Lysogeny is

maintained by the constitutive Prep promoter, which expresses the active (truncated) form
of the repressor protein (44).
In contrast to Lambda phage, the lytic/lysogenic switch in BPs is determined by
the integration event (13). During early gene expression from promoters PR and Prep, fulllength repressor proteins are synthesized, but are rapidly targeted for proteolysis by the
ssrA-like tag located at the C-terminal end of the protein (44, 70). Upon integration, the
ssrA-like tag is removed and the active (truncated) repressor is expressed (44).
Continuous degradation of the viral form of repressor leads to the expression of genes for
lytic growth (44). In this manner, superinfection immunity is not from the viral form of
the repressor protein, but from the truncated form (40).

The integration-dependent

immunity mechanism of BPs illustrates a unique method some mycobacteriophages use
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to lysogenize their hosts and also demonstrates the different mechanism that have
evolved to regulate the lytic and lysogenic decision.
Lysogenic Conversion
In 1927, researchers demonstrated an unusual phenomenon where previously nonpathogenic bacteria were converted to pathogenic forms after they were grown in the
presence of filtered media from a pathogenic strain (3, 67). It would be several decades
before phages were proven to be responsible for the pathogenesis of many bacteria, like
Corynebacterium diptheriae and Vibro cholera. Scientists are still uncovering more host
behaviors or traits contributed by temperate phages (4, 68). Lysogenic conversion has
played an important role in the diversification of bacterial species and is one of the major
contributors to bacterial pathogenesis (3, 69). Prophage-induced fitness advantages are
under strong selective pressures to be maintained within the bacterial population leading
to strain variation and over time possibly speciation (31, 34, 36, 37).
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MATERIALS & METHODS

Bacterial Strains and Mycobacteriophages
Bacterial strains and mycobacteriophages used in this study are listed in Table 1.
Growth Conditions
Unless otherwise noted, the growth conditions for all plating and liquid cultures
were incubated at 37°C, with liquid cultures shaking at 250 rpm.
Growth Media for Wild-type M. smeg
Wild-type (WT) M. smeg was routinely retrieved from archived frozen stocks and
streaked onto appropriate plate media using the standard streak plate technique. The
plate was incubated for approximately 4 days. After growth, plates were stored in 4°C
and used for several weeks. The inoculation from a plate into liquid media is the first
generation of growth (denoted as P1FF). To prepare a P1FF cultures, an independent
colony was aseptically transferred into the liquid medium, 7H9 Complete with Tween80
(Appendix I-C), and incubated for 4 days. For bacteriophage plating experiments, a
subculture of the P1FF was prepared by diluting the P1FF 1:100 in 7H9 Complete
without Tween80 (Appendix I-B). The subculture was the second generation of growth
(denoted as P2FF) and was also incubated for 4 days. All cultures were stored at 4°C
after growth.
Growth Media for E. coli
Escherichia coli (E. coli.) cells were grown in LB Broth (Appendix I-H).
Transformants were grown in LB broth supplemented with Kan (final concentration
50 µg/mL). E. coli cultures were incubated overnight, unless otherwise noted.
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Table 1. Host bacteria, lysogens, bacterial strains, vector and mycobacteriophages
Host Bacteria

Relevant characteristics

Reference

MC2155

Wild-type M. smeg

42

XL1-Blue

endA1 gyrA96(nalR) thi-1 recA1 relA1 lac
glnV44 F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15]
hsdR17(rK- mK+)

77

Strains

Relevant characteristics

Reference

RK1421

Lysogen containing MooMoo-T

This work

RK1422

Lysogen containing MooMoo-C

This work

RK1405

XL1; pLAM-12+gp43;kanR

This work

RK1406

XL1; pLAM-12+gp44;kanR

This work

RK1407

MC155; pLAM-12+gp43;kanR

This work

RK1408

MC155; pLAM-12+gp44;kanR

This work

RK1409

MC155; pLAM-12;kanR

This work

RK1410

XL1; pLAM-12+gp19 (WT);kanR

This work

RK1411

XL1; pLAM-12+gp42;kanR

This work

RK1412

XL1; pLAM-12+gp19 (mutant);kanR

This work

RK1413

MC155; pLAM-12+gp42;kanR

This work

RK1415

MC155; pLAM-12+gp19 (WT);kanR

This work

RK1416

MC155; pLAM-12+gp19 (mutant);kanR

This work

RK1291

pLAM-12 Vector; kanR

Phages

Relevant characteristics

Reference

MooMoo-T

WT phage, Forms turbid plaques

This work

MooMoo-C

Mutant, Forms clear plaques; (2017)

This work

43
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Growth Media Modifications for M. smeg Clones
AD supplement and CaCl2 can inhibit the effectiveness of the acetamidase
promoter in the vector pLAM-12 (41). There is also evidence to suggest the acetamidase
promoter may not be tightly regulated in the presence of succinate (41). For the gp42,
gp43 and gp44 clones, P1FF’s were prepared in 7H9 Complete with Tween80
supplemented with Kanamycin (Kan) to a final concentration of 50 µg/mL, then
incubated for 4 days. P2FF subcultures were prepared by diluting the P1FF 1:100 into
two different medias: 7H9-ADC (Appendix I-J) and Induction Media (Appendix I-K).
Cultures were incubated for 4 days. These cultures formed poor lawns with severe
clumping of the cells. Subsequently, all clones were grown in 7H9 Complete media (with
and without Tween80) supplemented with Kan to a final concentration of 50 µg/mL. All
cultures were stored at 4°C after growth.
Plate Media for Wild-type M. smeg
WT M. smeg was plated on Luria Agar Plate Media supplement with
Carbenicillin (CB) and Cycloheximide (CHX; Appendix I-D). These plates are denoted
as LA+CB+CHX.
Plate Media for pLAM-12 Clones
Selected M. smeg transformants and pLAM-12 clones were plated on Luria Agar
Plate Media supplemented with CB, CHX and Kan (Appendix I-E). These plates are
denoted as LA+Kan.
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Plate Media for Induction of pLAM-12 Clones
Selected pLAM-12 clones were plated on Luria Agar Plate Media supplemented
with CB, CHX, Kan and Acetamide (Appendix I-F).

These plates are denoted as

LA+Acet.
Plate Media for E. coli
E. coli transformants were plated on LB Agar Plate Media supplemented with
Kan (Appendix I-I). These plates are denoted as LB+Kan.
10-fold Serial Dilutions
Ten-fold serial dilutions were performed as required. The undiluted sample is
denoted as 100. Phage lysates were diluted in Phage Buffer (PB; Appendix II-E), while
cells were diluted with the appropriate media. Figure 6 (below) depicts a general 10-fold
serial dilutions scheme.

Figure 6. Illustration of 10-fold serial dilutions.
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Preparations with 7H9 Top Agar (Phage Plating)
Phage plating typically involved transferring 4.5 mL of molten 7H9 Top Agar
(Appendix I-G) into a glass culture tube containing 0.5 mL of cells and phage. The entire
contents of the culture tube were mixed thoroughly by pipetting up and down, and then
the contents were transferred onto the appropriate plate media.
Preparations with 7H9 Top Agar (Bacterial Lawn)
Plating of WT M. smeg or pLAM-12 clone lawns were performed as described
above, however no phages were present in the culture tube. Lawns were prepared on the
appropriate plate media.
Phage Growth
Mycobacteriophage MooMoo was grown from a frozen archived stock by
scraping some of the frozen material and spotting it onto a lawn of M. smeg. The WT
M. smeg lawn was prepared on a LA+CB+CHX plate as described in “Preparations with
7H9 Top Agar (Bacterial Lawn)”. After 24 hours of incubation, the area of phage growth
was transferred into 100 µL of PB using a micropipette tip to stab through the Top Agar
layer down to the bottom plate agar. This process is noted as “plugging”. Figure 7
(below) demonstrates how the area of phage growth was plugged. The agar, containing
the phage, was incubated in the PB at room temperature for 1 hour to allow diffusion of
phage particles into the buffer. A 10-fold serial dilution was performed (to 10-6). For
plating, 10 µL of each dilution 10-3  10-6 was transferred into 0.5 mL aliquots of P2FF
M. smeg cells and incubated at room temperature for 30 minutes to allow for phage
binding. Molten 7H9 Top Agar was aseptically transferred, mixed, then dispensed onto a
LA+CB+CHX plate. After solidifying, the plates were inverted and incubated overnight.
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Figure 7. Plugging a plaque.

Plaque Assays for Purifications
To purify a clonal population, three rounds of plaque purifications were necessary
to ensure consistent plaque morphology. A typical purification involved plugging the
most isolated plaque into PB, incubation at room temperature, 10-fold serial dilutions,
phage binding to M. smeg cells, plating onto appropriate media and then incubating the
plates overnight.
Preparing 1-Plate Lysates (1PL)
After purifying a clonal population, the plate containing the most confluent
plaques (denoted as the “webbed plate”) from the final round of purification, was flooded
with 6 mL PB and incubated at room temperature for 5 hours. The incubation allowed
the phage from the plate to diffuse into the buffer. The PB containing the phage was
harvested with a 5 mL syringe and filter-sterilized with a GE Healthcare WhatmanTM
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Puradisc 0.2 µM syringe filter (Fisher Cat. No. 05-713-386) into a 15 mL tube. Plaque
assays are used to estimate the concentration, or titer, of phage present in the lysate.
Plaques are formed by infectious phage particles, thus noted as plaque forming units
(PFU). To titer each 1PL, a 10-fold serial dilution out to 10-7 was performed. Dilutions
10-2 10-7 were plated onto LA+CB+CHX plates for each 1PL and then incubated
overnight. The titer was calculated as indicated, using a plate with a countable number of
plaques. The formula below was used to determine the titer.

Preparing High Titer Lysates
The High Titer Lysate (HTL) was used for phage DNA isolation, archiving and
electron microscopy. From the 1PL, a 10-plate lysate, also known as a HTL, was
prepared. The concentration necessary to achieve 10 webby plates from the 1PL, was
empirically determined. From the 1PL, a 10-fold serial dilution was performed out to the
determined webbed plate dilution and then 100 µL of that dilution transferred into a 5 mL
aliquot of P2FF M. smeg cells. As previously described, the phage and cells were
incubated at room temperature, mixed with Top Agar and plated onto LA+CB+CHX
plates. The plates were incubated overnight, after which confluent plaques appeared on
all 10 plates. Each plate was flooded with 6 mL PB and incubated at room temperature
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for 6 hours. The lysate was harvested and filter-sterilized using a 50 mL CorningTM Tube
Top 0.22 μM vacuum filter-sterilization unit (Fisher Cat. No. 09-761-34). As described
above, plaque assays are used to estimate the titer of the HTL.
Transmission Electron Microscopy
Phage morphology was determined by electron microscopy. Prior to imaging and
analysis, lysate samples were concentrated by centrifugation. One mL of HTL was
transferred into a sterile microcentrifuge tube and centrifuged at 7,200 RCF at 4°C for 1
hour. The supernatant was discarded, after which the invisible phage pellet was
re-suspended in 50 µL of PB and incubated at 4°C overnight.
Phage DNA Isolation
Phage genomic DNA was isolated from HTL’s in a two-step process. First,
remnants of lysed bacterial cells, bacterial nucleic acids, proteins and lipids were
removed from the phage lysate. Second, phage DNA was released from the capsid using
a chaotropic agent and purified using a DNA binding resin. To begin, a 10 mL aliquot of
HTL was transferred into a sterile Oak Ridge tube (Fisher Cat. No. 05-0563-7G) and
equilibrated to room temperature. To enzymatically degrade any bacterial DNA and
RNA, 40 µL of Nuclease Mix stock (Appendix II-H) was added, mixed by gentle
inversion and incubated at 37ºC for 30 minutes. After 30 minutes, the treated lysates
were removed from 37ºC and then incubated at room temperature for 1 hour.

To

concentrate the phage particles, 4 mL of Phage Precipitation Solution (Appendix II-L)
was transferred into the nuclease-treated lysate, mixed by inverting 3 times, then
incubated at 4ºC for approximately 4 hours. The phage particles were pelleted via
centrifugation at 17,217 RCF for 20 minutes at 4ºC. The pellet was re-suspended with
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0.5 mL sterile water and incubated at room temperature for 10 minutes. To purify the
phage DNA from the phage particles, 2 mL of pre-warmed (37ºC) Promega WizardTM
DNA Cleanup Resin (Wizard DNA Cleanup System; Fisher Cat. No. PR-A7280) was
added and repeatedly pipetted to break up the pellet. The mixture was transferred to a
Wizard® Minicolumn attached to a syringe barrel and the material pushed through the
minicolumn. The resin contains a blend of microscopic polymer beads and guanidinium
thiocyanate. The polymer beads are unable to pass through the fine mesh of the column
filter, thus it packs tightly into the column. Contaminants were removed from the bound
DNA by washing the column with 80% isopropanol. Wash steps were performed by
pushing 2 mL 80% isopropanol through the column. Each wash was followed by a
centrifugation step (12,045 RCF for 5 minutes). A final 1-minute centrifugation was
done to remove residual isopropanol and the columns were transferred to sterile
microcentrifuge tubes. Phage genomic DNA was eluted using 50 µL of pre-warmed
(85ºC) Elution Buffer (Appendix II-K) and incubated for 1 minute. The eluted DNA was
recovered by centrifuging the tube for 1 minute. A second elution using the same volume
of Elution Buffer (EB) into a new microcentrifuge tube was performed. The two eluates
were then combined into a single tube (approximately 100 µL combined volume). The
concentration of the pooled DNA was estimated using the ThermoScientific NanoDrop
Spectrophotometer (Fisher Cat. No. ND2000).
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Whole Genome Sequencing
Phage genomic DNA samples were sequenced at North Carolina University
Genomic Sciences Laboratory (NC-GSL). NC-GSL’s guidelines for sample submission
requires phage DNA be submitted at a concentration of 2 µg/120 µL. Two micrograms
of purified phage DNA was diluted in EB to the total requested volume of 120 µL and
shipped on ice overnight.
Phage Lysogeny Assays
Lysogeny assays were performed as described by the Actiobacteriophage
Database (72). This assay is used to determine how readily a phage forms lysogens in a
bacterial host. HTL’s were diluted in PB to 1010 PFU/mL then 100 µL was spread onto
LA+CB+CHX plates. A flame sterilized glass L-rod was used to spread the 100 µL of
phage over the surface of the plate. These plates are denoted as “seeded” plates. After
spreading the phage, selected dilutions of M. smeg cells were plated. “Unseeded” plates
were the control plates for the lysogeny assay. These plates only have dilutions of M.
smeg cells on the plate. Ten fold serial dilutions (to 10-7) of P2FF M. smeg cells were
plated. The entire volume of each dilution set (10-510-7) was transferred into a culture
tube, mixed with Top Agar, and then plated onto either the seeded or unseeded plates.
Once solidified, the plates were incubated for 96 hours.

Percent efficiency was

calculated by counting the colony-forming units (CFU) on the seeded plates and dividing
that number by the CFU on the unseeded plates, then multiplying the quotient by 100%.
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Creating Lysogens
To create a lysogen, a 2x2 grid was drawn on the bottom of two LA+CB+CHX
(see diagram below).

Lawns of WT M. smeg were prepared on each plate as previously described. A 10-fold
serial dilution (to 10-8) was prepared from the HTL and 5 µL of each dilution (10-110-8)
was spotted onto the plates. The plates were incubated and monitored daily until mesas
(overgrowth of bacterial cells) formed within the phage spots. Cells from the centers of
each mesa were streaked onto a LA+CB+CHX plate using the standard streak plate
technique. After incubating for four days, colonies were purified by streak plating. As
described in “Growth Media for Wild-type M. smeg”, P1FF liquid cultures were
inoculated from independent colonies in 7H9 Complete with Tween80, incubated for 4
days, subcultured in 7H9 Complete without Tween80 and then incubated for 4 days. The
presence of the prophage was confirmed before the lysogens were archived (Table 1).
Sequential Restriction Digestion of DNA
Vector (pLAM-12) and plasmid DNA from E. coli and M. smeg clones was
digested sequentially with BamHI and NheI restriction enzymes. The first digestion
included: BamHI restriction enzyme (final concentration 5 U), elected amount of DNA,
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BamHI enzyme buffer (1/10th volume) and quantum sufficient (Q.S.) with sterile water.
Reactions were incubated at 37ºC for 2 hours. The enzyme and buffer were removed
using the QIAquick® PCR Purification Kit (Qiagen Cat. No. 28104), after which a 5 μL
aliquot was reserved for gel observation. The second digestion reaction included: NheI
restriction enzyme (final concentration 10 U), digested and purified plasmid DNA, NheI
enzyme buffer (1/10th volume) and Q.S. with sterile water. Reactions were incubated at
37ºC for 2 hours, followed by removal of the enzyme and buffer with the QIAquick®
PCR Purification Kit and another 5 μL aliquot reserved for gel observation. To prepare
each sample for gel electrophoresis, a 5 μL aliquot of the digest was added to 3 μL of
sterile water, 2 μL of 5X Glycerol Gel-Loading dye (Fisher Cat. No. BP645-5) and gently
mixed by pipetting. Gel electrophoresis conditions, as well as the preparation of agarose
gels are described in “Gel Electrophoresis” below. All samples were stored at -20ºC.
Simultaneous Restriction Digestion of DNA
Plasmid DNA harvested from E. coli and M. smeg clones was simultaneously
digested with NdeI and NheI restriction enzymes. The reaction consisted of NdeI and
NheI restriction enzymes (final concentrations 5 U and 10 U, respectively), plasmid
DNA, CutSmart NdeI enzyme buffer (1/10th volume) and Q.S. with sterile water.
Reactions were incubated at 37ºC for 2 hours. After incubation, the enzymes and buffer
were removed using the QIAquick® PCR Purification Kit and a 5 μL aliquot was
reserved for gel observation. All samples were stored at -20ºC.
Gel Electrophoresis
Fisher Scientific electrophoresis systems were used to run agarose DNA gels
(Fisher Cat. No. FB-SB-710, FB-SBR-1316).
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Agarose gels were prepared at a

concentration of 0.8% agarose in 40 or 100 mL of 1X Tris-Acetate, EDTA buffer
supplemented with ethidium bromide (EtBr, final concentration 0.625 μg/mL). The 1X
Tris-Acetate, EDTA (TAE) buffer was diluted from a 10X stock (Lonza AccuGeneTM
10X TAE Buffer, Fisher Cat. No. BMA50844). DNA standards included a 1 kb ladder
(NEB Cat. No. N3232S; 500 μg/mL) and/or a 100 bp ladder (NEB Cat. No. N3231S; 500
μg/mL). Both standards were prepared as 10 μL aliquots (final concentration of 1 μg) in
EB and 5X glycerol loading dye.

Gels were run in 1X TAE buffer at 100V for

approximately 120 minutes.

Table 2. Restriction Enzymes
Name

Relevant Characteristics

NEB Cat. No.

BamHI

5’ – G / GATCC – 3’; 20,000 U/mL

R0136S

NheI

5’ – G / CTAGC – 3’; 10,000 U/mL

R0131S

NdeI

5’ – CA / TATG – 3’; 20,000 U/mL

R0111S

Polymerase Chain Reaction (PCR)
The Phusion® High-Fidelity DNA Polymerase Kit (NEB Cat. No. M0530S) was
used for all PCR reactions. Phusion polymerase has enhanced processivity and 50x
higher fidelity than Taq polymerase. A typical 20 μL PCR reaction consisted of Phusion
GC Buffer (final concentration 1X), Deoxynucleotide (dNTP’s) Solution Mix (final
concentration 200 μM each), selected forward and reverse primers (final concentrations
0.5 μM each), Phusion Taq Polymerase (final concentration 2.5 U/μL), template DNA
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and sterile water to volume. The Phusion thermocycling conditions were programmed
into the Vappoprotect® Mastercycler® (EppendorfAG Cat. No. 6321) and consisted of
an initial denaturation at 98ºC for 30 seconds followed by 30 cycles of 98ºC for 10
seconds, 56ºC for 30 seconds, 72ºC for 30 seconds, and a final extension of 72ºC for 5
minutes. After completing the cycles, the reactions were held at 4ºC indefinitely. Table
3 contains the PCR and cloning oligonucleotides used in this work.
Microfiltration
The Amicon® Ultra-0.5 mL Centrifugal Filters (EMD Millipore Cat. No.
UFC510096) were used to concentrate DNA samples and facilitate buffer exchanges.
For gel extractions, the filter device was placed in the collection tube and 0.4 mL of
sterile water was added to the filter. The eluted DNA processed by gel extraction (see
“Gel Extraction” below) was transferred into the 0.4 mL sterile water and gently mixed
by pipetting. The filtration device was centrifuged at 12,045 RCF for 10 minutes, after
which the filtration unit transferred into a clean collection tube. The filter containing the
DNA was washed with 0.5 mL sterile water and centrifugation repeated. Before placing
into final collection tube, 15 μL of sterile water was carefully added to each filter
membrane in the device. The filtration device was then inverted and inserted into a
sterile microcentrifuge tube and centrifuged at 6,708 RCF for 2 minutes to recover the
DNA retained by the filter. Approximately 50 μL of the sample was recovered. The
procedure was also used to microfilter ligation reactions. The filtration device was
directly inverted into the final collection tube after the final wash and approximately
20 μL was recovered. All samples were stored at -20ºC.
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Table 3. Oligonucleotides
Name

Sequence 5’3’

Specifications

MTP-F

acagcGGATCCCGGTTCTACAAG
CGTGATGTGAC

Used to amplify gp19

MTP-R

caagaGCTAGCGTGAGGTCGGCA
CCTG

Used to amplify gp19

MTP1

GTCGAGCAAGGGTTGCTG

Forward; Confirm gp19

MTP2

CGATAGGCACTGATGGTGC

Forward; Confirm gp19

MTP3

GACGTCGCGAACAAGGTC

Forward; Confirm gp19

gp42-F

gatcaCATATGGTTGAGACAAACA
ACG

Used to amplify gp42

gp42-R

gatcGCTAGCATGTTCGATTCTGA
ACTTG

Used to amplify gp42

gp43-F

ttcaaGGATCCCGGCTACTAGGGG
ACACTG

Used to amplify gp43

gp43-R

ccgacGCTAGCCTTTCCTCTCGGTG
TCGGT

Used to amplify gp43

gp44-F

cattcGGATCCCAAGCGTTCGGGGA
CATC

Used to amplify gp44

gp44-R

gtaatGCTAGCCACGCCGGCGTAG
AAG

Used to amplify gp44

PLAMF1

CCGCAGTTGTTCTCGCATAC

Confirm vector/inserts

PLAMF2

CGGTCATCGCCGTGATC

Confirm vector/inserts;
GeneWiz sequencing gp19

PLAMR1

CGGCCTCGAGCAAGAC

Confirm vector/inserts

PLAMR2

GATTGCCCGACATTATCGCG

Confirm vector/inserts;
GeneWiz sequencing gp19

For cloning primers, lowercased segments were randomly chosen nucleotides. The
restriction site is incorporated into the oligonucleotide and are highlighted as follows:
BamHI, NheI, NdeI.
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Gel Extraction (Phenol-freeze Method)
To purify DNA from agarose gels, two alternative procedures were used (73).
After running DNA on an agarose gel (supplemented with EtBr), the gel was placed on a
UV light table and a sterile razor was used to cut out the desired bands. The gel
fragments were carefully transferred into microcentrifuge tubes and then chopped into
smaller pieces inside the microcentrifuge tube before adding 0.9 mL of equilibrated
phenol (Affymetrix Cat. No. J75829). After thoroughly blending, the gel-phenol mixture
was frozen at -80ºC for 10 minutes then immediately centrifuged at 12,045 RCF for 10
minutes.

The aqueous phase containing the DNA was transferred into a sterile

microcentrifuge tube.

Three successive chloroform wash steps were performed by

adding an equal volume to the aqueous phase followed by centrifugation at 12,045 RCF
for 30 seconds. After the final chloroform wash, 1/10th volume of 3 M Na(C2H3O2)2, pH
5.2 and 2 volumes of cold (4ºC) 100% ethanol was added to the aqueous phase.
Typically, the solution was allowed to incubate at -20ºC overnight. The next day, a
precipitate was formed by centrifuging the sample at 11,337 RCF for 30 minutes at 4ºC.
The supernatant was decanted and the invisible pellet air-dried briefly before resuspending in 0.1 mL EB. Samples were concentrated and purified as described in
“Microfiltration”.
Ligations
T4 DNA Ligase (NEB Cat. No. M0202S) was used for each ligation. A typical
20 L ligation reaction consisted of 2 L of the 10X T4 DNA Ligase Reaction Buffer
(NEB Cat. No. B0202S), 1 L of T4 DNA Ligase, purified insert and/or vector and Q.S.
with sterile water. The amount of each insert was estimated by examining the purified
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fragments on agarose gels. Equamolar amounts of vector and insert were mixed in each
ligation reaction. A vector only control ligation reaction was also performed. Ligations
were incubated at 14ºC overnight, and then inactivated by heating at 65ºC for 20 minutes.
After heat inactivation, the ligation buffer was removed by ultrafiltration (see
“Microfiltration”). The recovered volume (approximately 20 L) was placed in the
Labconco Centrivap Concentrator (Centrivap Cat. No. 7810000, Centrivap Rotor Cat.
No. 745500) to further concentrate the sample to roughly 10 L. All samples were stored
at -20ºC.
Plasmid DNA Isolation
Plasmid DNA was isolated from 5 mL cultures of saturated cellular growth from
both M. smeg and E. coli transformants. A 5 mL culture was centrifuged at 1,299 RCF
for 10 minutes at 4ºC. The supernatant was discarded and the pellet was re-suspended in
2.5 mL 10 mM MgSO4 (Appendix II-Gi). One mL of the cell suspension was transferred
into a sterile microcentrifuge tube and centrifuged at 4,293 RCF for 15 minutes at 4ºC.
The supernatant was carefully decanted and an additional 1 mL aliquot of the cell
suspension was added into the tube containing the pellet.

The centrifugation was

repeated and the supernatant discarded. Plasmid DNA was isolated using the QIAprep®
Spin Miniprep Kit (Qiagen Cat. No. 27104) following the manufacturer’s protocol.
Briefly, the cell pellet was re-suspended and heavily vortexed in 0.25 mL of Buffer P1
(which contains RNase A and LyseBlue); 0.25 mL of Buffer P2 was added and mixed by
inverting 4-6 times; 0.35 mL of Buffer N3 was added and mixed by inverting until the
solution was neutralized and the LyseBlue reagent was colorless. The solution was
centrifuged at 11,337 RCF for 10 minutes, after which 0.8 mL of the supernatant was
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transferred into a DNA binding column in a microcentrifuge tube. The column was
centrifuged at 11,337 RCF for 60 seconds then washed with 0.5 mL of Buffer PB and
repeated centrifugation. A second wash was done with 0.75 mL of Buffer PE followed
by centrifugation. A final centrifugation for 60 seconds was done prior to placing the
column in a sterile microcentrifuge tube. The plasmid DNA was eluted by pipetting
50 L EB onto the surface of the column followed by centrifugation. The flow through
contained purified plasmid DNA. All plasmid DNA samples were stored at -20ºC.
Plasmid Vector DNA Isolation (pLAM-12)
Strain RK1291 was streaked onto an LB+Kan plate and incubated overnight. A
5 mL overnight culture was prepared as described in “Growth Media for E. coli”. The
overnight culture was diluted 1:1000 in 100 mL LB Broth+Kan and incubated for 24
hours. The next day, the culture was divided into 50 mL conical centrifuge tubes.
Plasmid DNA was harvested using the QIAfilter Midi Kit (Qiagen Cat. No.12243)
according to the manufacturer’s instructions with the exception of the last two steps.
After isopropanol was added to precipitate the DNA, 1 mL aliquots were transferred into
microcentrifuge tubes and centrifuged at 11,337 RCF for 30 minutes at 4ºC.

The

supernatants were discarded and the tubes were drained by inverting them onto a clean
paper towel for 5 minutes to remove any residual isopropanol.

The DNA was re-

dissolved by serially transferring 100 L of EB from tube-to-tube. To improve DNA
recovery, a second serial transfer was performed using 50 L EB.

The final

microcentrifuge tube contained approximately 150 L of vector DNA. Vector DNA was
stored at -20ºC.
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Plasmid Sequencing
To confirm the sequence of the DNA constructs generated during this study,
purified plasmid DNA was sequenced by GeneWiz. The size of the DNA insert in the
gp19 clone required multiple sequencing reactions to obtain the full sequence of the
cloned DNA. Forward primers MTP1, MTP2 and MTP3 were designed to be roughly 700
base pairs apart.

Vector specific forward and reverse oligonucleotides PLAMF2 and

PLAMR2 were also used to verify the orientation of the sequence within the vector. Primer
sequences are listed in Table 3. Per GeneWiz sequencing submission guidelines, plasmid
DNA for each construct was calculated to 0.8 g and sequencing primers were added to a
final concentration of 5 M.
Preparing M. smeg Electrocompetent Cells
M. smeg electrocompetent cells were prepared according to Broussard (52) with
the following modifications: a 50 mL P1FF culture in 7H9 complete with Tween80 was
prepared in a sterile non-baffled flask and incubated for approximately two days. In
order to obtain an OD600 of 0.8, 50 mL overnight cultures were prepared by staggering
the inoculation volumes of the P1FF culture and the incubation start/end times. These
subcultures were prepared using 7H9 complete with Tween80 in a sterile non-baffled
flask. The next day, the OD600 was checked until one of the cultures reached 0.8. The
cells were transferred into a 50 mL tube and incubated on ice for 1 hour.

After

incubation, the tubes were centrifuged at 3,000 RCF for 10 minutes at 4ºC.

The

supernatant was carefully discarded and the cells were washed with ice-cold 10%
glycerol (Appendix II-Ai) to remove salts. Three wash steps were performed using 1/2
volume, 1/4 volume and 1/8 volume of ice-cold 10% glycerol, respectively. After the
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final wash, the pellet was re-suspended in 3 mL ice cold 10% glycerol and aliquotted in
sterile microcentrifuge tubes (100 L/tube). The competent cells were stored at -80ºC
until further use.
Preparing E. coli Electrocompetent Cells
To prepare E. coli electrocompetent cells, a 5 mL overnight culture was prepared
in LB broth and incubated. The next day, the overnight culture was diluted 1:100 in LB
in a sterile non-baffled flask. The culture was incubated until the OD600 = 0.4. After
reaching OD600 = 0.4, the culture was equally divided into 2 – 50 mL tubes. The tubes
were centrifuged for 3,000 RCF for 10 minutes at 4ºC. The supernatants of each tube
were immediately decanted and the pellets re-suspended with ice-cold sterile water. Two
wash steps were performed. For the first wash, an equal volume of ice-cold sterile water
was used. For the second wash, 1/2 volumes of ice-cold sterile water used. After the
final wash, the pellets were re-suspended with 1.3 mL ice-cold 10% glycerol and
transferred into pre-chilled (on ice) microcentrifuge tubes. The microcentrifuge tubes
were centrifuged at 5,000 RCF for 10 minutes at 4ºC, after which the supernatants were
carefully discarded. Each pellet was re-suspended thoroughly with 0.3 mL ice-cold 10%
glycerol and aliquotted into sterile microcentrifuge tubes (50 L/tube), then stored at 80ºC until further use.
Electroporation into M. smeg
All cells and materials were maintained on ice during this procedure.

The

electroporation for M. smeg was performed using slight modifications to Broussard’s
protocol (52). DNA was calculated to a final concentration of 150 ng for each sample.
The M. smeg electrocompetent cells were removed from -80ºC and incubated on ice for
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10 minutes. DNA was added to the cells and mixed by gently pipetting. The DNA and
cells were incubated on ice for 10 minutes while the electroporation conditions were
entered into the BioRad Gene Pulser XcellTM Electroporation System (BioRad Cat. No.
165-2660) PC module. For M. smeg, electroporation conditions were as follows: voltage
2.5kV, capacitance 25 F, and resistance 1000 Ω. After the 10 minute incubation, the
DNA and cells were transferred into a Bulldog 2mm Electroporation Cuvette (Fisher Cat.
No. NC04493637), placed into the ShockPod and electroporated.

Time constants

averaged between 18 – 19 milliseconds. For recovery, the electroporated cells were
transferred into a 15 mL tube with 1 mL of 7H9 complete with Tween80 and incubated at
37ºC, with shaking at 250 rpm for 2 hours. Afterwards, the cells were spread on selective
media plates in increments of 1 L, 5 L and 50 L then incubated for 3-4 days.
Transformants were subjected to one round of purification by streaking onto appropriate
selective media plates. Liquid cultures (P1FF and P2FF) were prepared as previously
described in “Growth Media Modifications for M. smeg Clones”. P2FF liquid cultures
were used in phage spot plating experiments.

P1FF liquid cultures were used for

archiving and harvesting plasmid DNA (see “Plasmid DNA Isolation”).
Electroporation into E. coli
All cells and materials were maintained on ice during this procedure. The cells
and DNA mixture were transferred into a Bulldog 2 mm cuvette and electroporated using
the BioRad Gene Pulser XcellTM Electroporation System programmed with the following
conditions: voltage 2.5kV, capacitance 25 F, and resistance 200 Ω. Time constants
were typically 5.1 milliseconds. For recovery, the electroporated cells were re-suspended
in 1 mL Super Optimal Broth with Catabolite (SOC) Repression (Appendix I-L),
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transferred to a 15 mL tube and incubated at 37ºC, with shaking at 250 rpm for 1.5 hours.
Afterwards, the cells were spread onto selective media in increments of 50 L, 100 L
and 150 L then incubated for 24 hours. Transformants were subjected to one round of
purification by streaking onto appropriate selective media plates. Liquid cultures were
prepared as described in “Growth Media for E. coli”. Plasmid DNA was isolated from
overnight liquid cultures (see “Plasmid DNA Isolation”) to use in further experiments.
Phenotypic Microarray Analysis (Biolog)
Phenotypic microarray analysis was performed according to the manufacturers
protocol (Biolog, Inc.). Frozen stocks of WT M. smeg and lysogenic strains RK1421 and
RK1422 were each streaked onto a LA+CB+CHX plate and incubated for 4 days. Two
different phenotypic microarray additive solutions (“PM Additive Solutions”) were
prepared for the Phenotypic MicroArrayTM (referred to as “PM plates”) Panels. PM 1
and 2A Carbon Utilization Assays (Biolog Cat. No. 12111, 12112) require PM Additive
Solution 1 (Appendix II-M). PM 3B Nitrogen Utilization Assay (Biolog Cat. No. 12121)
and PM 4A Phosphorus and Sulfur Utilization Assay use PM Additive Solution 3
(Appendix II-N). The plates were removed from incubation and immediately scraped
with a sterile swab dipped in 1.2% Tween80 (Appendix II-Di) and mashed along the side
of a 50 mL tube. The cells were suspended in 20 mL of Inoculating Fluid IF-0a GN/GP
Base (Biolog Cat. No. 72268) and mixed thoroughly by gently pipetting. The OD600 of
the cell suspension was measured to match that of the 85%T Turbidity Standard (Biology
Cat. No. 3441). For PM 1 and 2A, the following were mixed into another 50 mL tube:
1.76 mL cell suspension, 2 mL of the PM Additive Solution 1, 0.24 mL Redox Dye Mix
G (Biolog Cat. No. 74227) and 20 mL of IF-0a GN/GP Base. PM 3B was prepared by
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mixing: 0.88 mL cell suspension, 1 mL of the PM Additive Solution 3, 0.12 mL Redox
Dye Mix G and 10 mL of IF-0a GN/GP Base. PM 4A was prepared the same as PM 3B
in a separate 50 mL tube. Plates were inoculated with the mixtures (100 L/well) and
incubated at 37ºC. If the cells metabolize the nutrient implanted in the well of the plate,
the tetrazolium present in the Redox dye turned purple as a result of a reduction reaction.
Every 24 hours for 4 days, the plates were removed from incubation and color changes
were visibly noted, then the OD595 recorded on a Molecular Devices SpectraMax 340PC
Microplate Spectrophotometer (Marshall Scientific Cat. No. MD-S340). After readings,
the plates were returned to incubation until the 4th day, where no significant color
changes or readings were recognized and the plates were discarded.
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RESULTS
The Science Education Alliance – Phage Hunters Advancing Genomics and
Evolutionary Science (SEA-PHAGES) program provides research-based curriculum to
novice students early in their science career. Through the SEA-PHAGES program,
student Cole Blair purified MooMoo from an environmental sample, characterized the
morphological features by electron microscopy and analyzed the phage DNA with
restriction enzyme digestion.

The genomic DNA was eventually sequenced and

bioinformatics analysis established that MooMoo was a singleton indicating no
appreciable genetic homology with other mycobacteriophages. Because of the novelty of
this phage, the goal of this project was to further characterize MooMoo, by exploring its
ability for form lysogens, its effect on host physiology and by identifying key regulatory
genes.
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MooMoo Plaque Phenotype Variation and Purification
Plaques are the clearings formed on lawns of infected bacterial cells. They can
vary in size and clarity depending on the phage infection pathway (lytic vs. lysogenic)
and plating conditions (e.g. temperature). MooMoo is a temperate phage resulting in
turbid, bulls-eye plaques (Figure 8A). However, during the phage growth process, I
discovered a clear plaque variant on a plate with confluent turbid plaques (Figure 8B).
The clear plaque mutant was purified as described in Materials and Methods under the
heading “Plaque Assays for Purifications”. Three rounds of purifications resulted in a
homogenous population of the clear plaque mutant phage.

The WT turbid plaque

forming phage was named MooMoo-T (T = turbid plaque phenotype) and the clear
plaque forming mutant phage was name MooMoo-C (C = clear plaque phenotype).
MooMoo-T and MooMoo-C 1PL’s and HTL’s were prepared as detailed in Materials and
Methods under the sections “Preparing 1-Plate Lysates (1PL)” and “Preparing High Titer
Lysates”. The results of 1PL titers for both MooMoo-T and MooMoo-C were 1x1011
PFU/mL. The HTL titer for MooMoo-T was 1.7x1011 PFU/mL and MooMoo-C was
1.8x1011 PFU/mL.
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Figure 8A-B. Plaque phenotype identification and purification. A) Individual purified
plaques of MooMoo-T plated from the HTL. B) Left side: *Representation of how the
clear plaque variant (arrow) appeared on confluent plate prior to purification; Right side:
Individual purified plaques of MooMoo-C plated from the HTL. (*Images of the original
plate of confluent plaques containing the clear plaque were not taken; this image was
obtained by plating 10-fold serial

dilutions
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of the

HTL of

MooMoo-T.)

MooMoo-T and MooMoo-C Sequence Comparisons
In 2012, the Pittsburgh Bacteriophage Institute completed the whole genome
sequencing of MooMoo-T (GenBank MH001449.1). Since MooMoo-T typically forms
turbid plaques, I sought to identify the mutation responsible for the clear plaque
phenotype of MooMoo-C. Genomic DNA for both MooMoo-T and MooMoo-C was
isolated and the samples were sequenced as detailed in the Materials and Methods under
the sections “Phage DNA Isolation” and “Whole Genome Sequencing”. The MooMoo-T
and MooMoo-C genomic DNA sequence alignments revealed a 1 base pair (bp) mutation
in MooMoo-C at genome coordinate 21,421. The mutation occurs in gene 19 (gp19) that
encodes the minor tail protein gene. (Figure 9A). The thymine to cytosine mutation
(TC) causes a Serine to Proline (SerPro) substitution in the protein sequence (Figure
9B).
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Figure 9A-B. MooMoo-T and MooMoo-C sequence comparisons. A) Top: Cropped
image from Phage Evidence Collection And Annotation Network (PECAAN) illustrating
the minor tail protein gene (name MTP) with outlined mutation in the dark red box.
Bottom: Cropped image from Phamerator illustrating the sequencing alignment between
MooMoo-T and MooMoo-C and the mutation. A dark red line between the cropped
images shows where the mutation occurs on both the top and bottom image. B) Ancillary
image illustrating the SerPro substitution between MooMoo-T and MooMoo-C.
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Transmission Electron Microscopy
Since the sequencing results indicated the mutation responsible for the clear
plaque phenotype occurred in the minor tail protein, electron microscopy was used to
determine if morphological differences existed between MooMoo-C and MooMoo-T
phage particles. Analysis of the images revealed no gross morphological differences in
capsid or tail structures between MooMoo-T and MooMoo-C (Figure 10A-B).

Figure 10A. MooMoo-T TEM images magnified 50,000x; Capsid size = 113 nm x 25
nm, Tail length = 225 nm.
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Figure 10B. MooMoo-C TEM images magnified 50,000x; Capsid size = 113 nm x 25
nm, Tail length = 225 nm
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MooMoo-T and MooMoo-C Lysogeny Assays
The phage lysogeny assays performed on MooMoo-T and MooMoo-C HTL’s to
determine how well each phage will form lysogens in a susceptible host. Both MooMooT and MooMoo-C HTL’s were diluted in PB to 1010 PFU/mL to ensure each seeded plate
was spread with the same amount of phage. The amount of HTL and PB were calculated
as follows:

Three trials (Trials 1 – 3) were performed and average efficiencies are reported in Table
4. For each trial, colony forming units (CFU) from the same dilution of M. smeg cells on
seeded and unseeded countable plates were used to calculate the percent efficiency.
Figure 11A-B demonstrates one of the plating trials.

Table 4. Percent efficiency
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Figure 11A-B. CFU’s on countable plates used to determine lysogeny efficiency. Plates
are shown with M. smeg cells that were diluted to 10-6. A) MooMoo-T seeded and
unseeded countable plates (CFU’s on seeded plate = 652, CFU’s on unseeded plate =
792). B) MooMoo-C seeded and unseeded countable plates (CFU’s on seeded plate = 8,
CFU’s on unseeded plate = 645).
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Phage Spot Plating on Lysogenic Strains
To confirm that MooMoo-T or MooMoo-C prophages were present in the
presumed lysogens, 10-fold serial dilutions of MooMoo-T and MooMoo-C HTL’s were
prepared and 5 µL aliquots of each dilution were spotted onto lawns of each lysogen.
The plates were incubated overnight and examined the next day. There were no spots
present on either plate (Figure 12A-B), indicating one of two formal possibilities: 1) the
phage growth was blocked due to the presence of the prophage, or 2) the bacterial cells
were resistant to phage infection. Further testing was necessary to confirm if the cells
were lysogenic.
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Figure 12A-B. Lysogens prevent superinfection by MooMoo-T or MooMoo-C. A)
Putative lysogen purified from MooMoo-T mesa was negative for MooMoo-T and
MooMoo-C growth. B) Putative lysogen purified from MooMoo-C mesa was negative
for MooMoo-T and MooMoo-C growth. The dilutions of each lysate are indicated on the
plates.
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Mitomycin C Treatment Does Not Induce Resident Prophages
Since lysogeny could not be confirmed solely on the absence of phage spotting, I
attempted to induce phage release with mitomycin C. Mitomycin C creates lesions in the
bacterial DNA, which signals that the cell’s DNA is critically damaged (76). The signal
of DNA damage activates the SOS response pathway, a pathway leading to cleavage of
the phage repressor and expression of phage lytic genes (76). Duplicated dilutions of the
cultures were prepared (1:1 and 1:4 dilutions) in 7H9 Neat (Appendix I-A). The purpose
of duplicating the dilutions was to use one as the control (no mitomycin C) and the other
as the test (added mitomycin C). Table 6 shows the results of mitomycin C induction.
The cultures were labeled as either MT (MooMoo-T) or MC (MooMoo-C) for the
resident prophage and with A (1:1) or B (1:4) to indicate the dilution. Cultures that were
supplemented with mitomycin C were labeled with “myc”.

Mitomycin C stock

(Appendix III-D) was added to the final concentration of 2 µg/mL and all cultures were
incubated at 37ºC, with shaking at 250 rpm for 24 hours. After growth, the cultures were
centrifuged at 3,000 RCF for 15 minutes at 4ºC. The supernatant of each sample was
filter-sterilized into a 15 mL tube with a GE Healthcare Whatman TM Puradisc 0.2 µM
syringe filter. A 10-fold serial dilution (to 10-3) was prepared for each filtrate and 5 µL
of each dilution was spotted onto lawns of WT M. smeg host cells. All plates were
incubated overnight at 37ºC. The cultures incubated with mitomycin C showed no
evidence of lytic activity. The single plaque that appeared in the highest concentration is
likely a contaminant or a spontaneously released phage. Control cultures (no mitomycin
C) showed significantly more plaques compared to the cultures that received mitomycin
C indicating that phage were spontaneously released (Figure 13A-B).
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The lack of

plaques from the mitomycin C treated cultures indicates MooMoo is not inducible by this
treatment. This evidence, coupled with the results of the superinfection immunity assay,
indicates that these cells do contain resident prophages. Cultures of the lysogens were
archived in Mycobacterium Freezing Media (Appendix II-Q) as strains RK1421 and
RK1422, respectively.

Table 5. Mitomycin C induction test
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Figure 13A-B. Mitomycin C treatment and confirmation of resident prophage. (myc =
mitomycin C added) A) Filter-sterilized supernatants from MooMoo-T lysogens. B)
Filter-sterilized supernatants MooMoo-C lysogens. Plaques produced by spontaneous
phage release are highlighted with yellow circles or arrows. The green arrow points to
the single plaque observed in a culture that received mitomycin C.
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Cloning and Analysis of Selected MooMoo Genes
To facilitate the cloning and analysis of selected MooMoo phage genes, a shuttle
vector that allowed controlled expression of the cloned gene was utilized. The pLAM-12
shuttle vector (Figure 14) is a high copy plasmid with an acetamidase promoter and a
Kanamycin (KanR) resistance gene.

The pLAM-12 (vector) DNA was purified as

detailed in “Plasmid Vector DNA Isolation (pLAM-12)”. The desired MooMoo genes
were amplified by PCR, digested and inserted between the promoter and the KanR gene
using BamHI or NdeI coupled with NheI restriction enzyme cut sites (Figure 14). To
prepare the vector, the plasmid DNA was digested either sequentially with BamHI then
NheI or simultaneously digested with NdeI and NheI. Restriction enzyme digestions
were verified on an agarose gel (Figure 15). The BamHI-NheI and the NdeI-NheI
digested DNA’s were gel purified.

A released fragment was visible during gel

extractions due to the increased concentration of DNA loaded for each vector (Figure
16A-B). The gel-purified vectors were analyzed on agarose gels to confirm quality and
estimate quantity for ligations (Figure 17A-B).
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Figure 14. Schematic of the pLAM-12 shuttle vector. The vector size is 6,758 bp.
Arrows for BamHI, NdeI and NheI restriction sites show their relative locations.

Figure 15. Restriction enzyme digestions on
the pLAM-12 vector DNA. Lane 1 = 1 kb DNA
Ladder, Lane 2 = Control (undigested vector
DNA), Lane 3 = vector DNA digested with
BamHI, Lane 4 = BamHI cut vector DNA after
digesting with NheI, Lane 5 = vector DNA
simultaneously digested with NdeI and NheI.
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Figure 16A-B. Pre-extraction agarose gels of digested pLAM-12 vector. Orange boxes
highlight the extracted bands present between the 6 kb and 10 kb ladder marker. Green
boxes highlight the released fragment (expected band size approximately 150 bp). A)
Vector DNA digested with BamHI and NheI. B) Vector DNA digested with NdeI and
NheI.
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Figure 17A-B. Analysis of the purified and digested pLAM-12 vector by agarose gel
electrophoresis. A) BamHI and NheI digested vector (expected band = 6.7 kb). B) NdeI
and NheI digested vector (expected band = 6.7 kb).
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PCR Amplification of Candidate Phage Genes
Based on bioinformatic predictions several candidate genes (gp42, gp43 and
gp44) were selected as the potential phage repressor. Oligonucleotides for amplifying
gp43, gp44 and gp19 were designed with incorporated restriction enzyme sites for
BamHI and NheI. Primers for gp42 were designed to include NdeI and NheI (Table 3).
The genes were amplified from phage genomic DNA and verified on an agarose gel
(Figure 18). PCR products for gp42, 43 and 44 were purified and concentrated using the
QIAquick® PCR Purification Kit.

The gp19 gene amplified from MooMoo-T and

MooMoo-C was gel purified.
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Figure 18. Analysis of the PCR amplified MooMoo genes 19, 42, 43 and 44 via agarose
gel electrophoresis. Lane 1 = 1kb DNA Ladder, Lane 2 = Negative control (PCR Master
Mix without DNA), Lanes 3 & 5 – 7 contain genes amplified from MooMoo-T genomic
DNA in the following order: Lane 3 = PCR products amplified with primer set MTP-F/R
(expected band size = 3033 bp), Lane 5 = PCR products amplified with primer set gp43F/R (expected band size = 433 bp), Lane 6 = PCR products amplified with primer set
gp44-F/R (expected band size = 998 bp) and Lane 7 = PCR products amplified with
primer set gp42-F/R (expected band size = 610 bp). Lane 4 = PCR products amplified
from MooMoo-C genomic DNA using primer set MTP-F/R (expected band size = 3033
bp). Lane 8 = 100 bp DNA Ladder.
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Cloning of Amplified Phage Genes into pLAM-12 Vector and Electroporation into
E. coli
The PCR products described above were digested similarly to the pLAM-12
vector. For gp19 (WT and mutant versions), gp43 and gp44, the PCR amplified DNA
was digested sequentially with BamHI then NheI. For gp42, the PCR amplified DNA
was digested simultaneously with NdeI and NheI (Figure 19A-B). The vector and inserts
were ligated overnight, purified and then electroporated into electrocompetent XL-1 Blue
cells.

Figure 20A-D illustrates the vector with the correctly inserted gene.

electroporated cells were plated on selective media.
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The

Figure 19A-B. Analysis of the digested PCR products by agarose gel electrophoresis. A)
Lane 1 = 1 kb DNA Ladder, Lane 2 = BamHI/NheI sequentially digested WT gp19
(expected band size = 3033 bp), Lane 3 = BamHI/NheI sequentially digested mutant
gp19 (expected band size = 3033 bp), Lane 4 = BamHI/NheI sequentially digested gp43
(expected band size

= 433 bp), Lane 5 = BamHI/NheI sequentially digested gp44

(expected band size = 998 bp), Lane 6 = 100 bp DNA Ladder. B) Lane 1 = 1 kb DNA
Ladder, Lane 2 = NdeI/NheI simultaneously digested gp42 (expected band size = 610
bp), Lane 3 = 100 bp DNA Ladder.
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Figure 20A-D.

Representations of cloned MooMoo genes.

A-D) The restriction

enzymes are represented by red (BamHI), green (NdeI) or blue (NheI) rectangles on the
left or right sides of the labeled gene.
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Purification and Confirmation of Selected E. coli Transformants
Kanamycin resistant transformants were selected and purified by streaking onto
selective media (Figure 21A-J). Pure colonies were then used to inoculate overnight
cultures. The overnight cultures were harvested and plasmid DNA was purified. Each
plasmid clone was verified using PCR and restriction analysis (Figure 22-25). The WT
and mutant gp19 clones consistently showed a 200 bp band in the PCR amplification
products (Figure 22). Restriction analysis of the mutant gp19 clones showed a potential
incomplete digestion (Figure 23). This was unexpected since the 3 kb product was gel
purified from phage genomic DNA. To determine if plasmid DNA purified from WT
and mutant gp19 clones contained the expected cloned genes, the plasmid DNA was
sequenced using primers MTP1, MTP2 and MTP3 to obtain complete coverage of the
cloned genes (Figure 26). After sequence verification of the cloned genes, the plasmids
were electroporated into M. smeg competent cells.
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Figure 21A-J. Kanamycin resistant transformants purified via streak plating. A) WT
gp19 transformants. B) WT gp19 streak plate. C) Mutant gp19 transformants. D)
Mutant gp19 streak plate. E) gp42 transformants. F) gp42 streak plate. G) gp43
transformants. H) gp43 streak plate. I) gp44 transformants. J) gp44 streak plate.
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Figure 22. Analysis of the PCR products amplified from the gp19 clones by agarose gel
electrophoresis. Orange box highlights non-specific amplification product at 200 bp.
PCR products were amplified from purified plasmid DNA clones of WT or mutant gp19
using MTP-F/R primer set; Lane 1 = 1 kb DNA Ladder, Lane 2 = PCR products
amplified from WT gp19 clone (expected band size = 3033 bp), Lane 3 = PCR products
amplified from mutant gp19 clone (expected band size = 3033 bp), Lane 4 = 100 bp DNA
Ladder.

65

Figure 23. Restriction enzyme analysis of the plasmid DNA clones of gp19 by agarose
gel electrophoresis. Lane 1 = 1 kb DNA Ladder, Lane 2 = Clone of WT gp19-digested
with BamHI (expected band size at 9.7 kb), Lane 3 = Clone of mutant gp19 (expected
band size at 9.7 kb), Lane 4 = Clone of WT gp19-digested with BamHI then NheI
(expected vector band size at 6.7 kb and released band at 3033 bp), Lane 5 = Clone of
mutatnt gp19-digested with BamHI then NheI (expected vector band size at 6.7 kb and
released band at 3033 bp; potential incomplete digestion), Lane 6 = 100 bp DNA Ladder.
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Figure 24A-B. Analysis of the PCR products amplified from gp42 and gp43 clones and
restriction enzyme analysis of the plasmid DNA by agarose gel electrophoresis. Multiple
exposures of the same gels are shown to improve the visibility of faint bands. Orange
boxes highlight the vector bands, while green boxes highlight the released bands. A)
Lane 1 = 1 kb DNA Ladder, Lane 2 = PCR products amplified from plasmid DNA clone
of gp42 using PLAM-F1/R1 primer set (expected band size = 837 bp), Lane 3 = plasmid
DNA clone of gp42 simultaneously digested with NdeI-NheI (expected vector band size
= 6.7 kb and released band = 837 bp). B) Left side gel: Lane 1 = 1 kb DNA Ladder, Lane
2 = PCR products amplified from plasmid DNA clone of gp43 using gp43-F/R primer set
(expected band size = 433 bp); Right side gel: Lane 1 = 1 kb DNA Ladder, Lane 2 =
Plasmid DNA clone of gp43 sequentially digested with BamHI then NheI (expected
vector band size = 6.7 kb and released band = 433 bp).
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Figure 25. Analysis of the PCR products amplified from gp44 clones and restriction
enzyme analysis of the plasmid DNA by agarose gel electrophoresis. Left side gel: Lane
1 = 1 kb DNA Ladder, Lane 2 = PCR products amplified from plasmid DNA clone of
gp44 using PLAM-F1/R1 primer set (expected band size = 1131 bp); Right side gel: Lane 1
= 1 kb DNA Ladder, Lane 2 = Plasmid DNA clone of gp44 sequentially digested with
BamHI then NheI (expected vector band size = 6.7 kb and released band = 1131 bp).
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Figure 26. Representation of gp19 gene sequencing coverage on plasmid. The relative
locations for the PLAM-F2/R2 primers are noted by the dark pink lines. The relative
locations for MTP-F1, MTP-F2 and MTP-F3 primers are marked by the light blue lines.
The TC mutation in mutant gp19 is noted by the purple box.
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M. smeg Transformant Plating and Purification
Purified plasmid DNA isolated from each clone in E. coli was electroporated into
M. smeg competent cells and plated onto selective media (Figure 27A-F). M. smeg was
also electroporated with pLAM-12 plasmid DNA without an insert as a control.
Kanamycin resistant transformants were purified by streaking onto selective media and
afterwards, pure colonies were used to inoculate 20 mL cultures. Unfortunately, only low
concentrations and poor quality of DNA was recovered from the M. smeg transformants.
Attempts to verify the plasmid DNA clones using PCR typically resulted in multiple
bands with significant non-specific amplification products (Figure 28-30). Because of
the low yield of plasmid, restriction enzyme digestions were rarely seen on agarose gels
(Figure 30).

However, the recovery of Kanamycin resistant transformants and the

rigorous authentication of the constructs isolated from E. coli, strongly supports the
presence of each clone in M. smeg.
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Figure 27A-F. Kanamycin resistant transformants in M. smeg cells. A) pLAM-12 vector
without insert. B) Cells electroporated with WT gp19 clone from MooMoo-T. C) Cells
electroporated with mutant gp19 from MooMoo-C. D) Cells electroporated with gp42
clone. E) Cells electroporated with gp43 clone. F) Cells electroporated with gp44 clone.
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Figure 28. Analysis of the PCR products amplified from the plasmid clone of M. smeg
(pLAM-12). Lane 1 = 1 kb DNA Ladder, Lane 2 = PCR products amplified from
plasmid DNA clone of pLAM-12 (no insert) using PLAM-F2/R2 primer set (expected band
503 bp), Lane 3 = 100 bp DNA Ladder.

72

Figure 29. Comparative analysis of M. smeg and E. coli PCR products amplified from
the plasmid clones. Lane 1 = 1 kb DNA Ladder, Lane 2 = PCR products amplified from
M. smeg plasmid DNA clone of gp43 using PLAM-F2/R2 primer set (expected band size =
614 bp), Lane 3 = PCR products amplified from E. coli plasmid DNA clone of gp43
using PLAM-F2/R2 primer set (expected band 614 bp), Lane 4 = PCR products amplified
from M. smeg plasmid DNA clone of gp44 using PLAM-F2/R2 primer set (expected band
size = 1223 bp), Lane 5 = PCR products amplified from E. coli plasmid DNA clone of
gp44 using PLAM-F2/R2 primer set (expected band 1223 bp).
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Figure 30. Analysis of the PCR products amplified from gp42 clones isolated from M.
smeg and restriction enzyme analysis of the M. smeg plasmid construct. Because of the
low concentration of DNA isolated from the M. smeg cells, the contrast had to be
significantly altered to visualize the DNA (boxed in orange). Lane 1 = 1 kb DNA
Ladder, Lane 2 = PCR products amplified from the gp42 clone using PLAM-F2/R2 primer
set (expected band size = 929 bp), Lane 3 = Simultaneous digestion of gp42 clone with
NdeI and NheI (expected vector band size = 6.7 kb and released band = 837 bp).
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Verification of Phage Repressor Activity
After successfully electroporating the gp42, gp43, gp44 and gp19 clones into
M. smeg and purifying the transformants by the streak plate technique, single colonies
were chosen and used to inoculate liquid cultures. After growth, lawns were prepared on
appropriate media. As a control, a lawn of cells with pLAM-12 (no insert) was also
plated. Serial dilutions of MooMoo-T and MooMoo-C lysates were spotted onto the
lawns and plates incubated for 24 hours. Evidence of phage infection was present at all
the dilutions except when lawns were prepared with the gp42 clones (Figure 31A-F).
This evidence strongly supports gp42 is the phage repressor and indicates that the gp42
clone expresses the phage repressor. It also shows that the other clones (gp19, gp43 and
gp44) have no effect on the plating of MooMoo-T or MooMoo-C.
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Figure 31A-F. Growth of MooMoo-T and MooMoo-C on cells that contain plasmid
clones gp19, gp42, gp43 or gp44. A) Positive control Cells with pLAM-12 (no insert)
clone. B) Cells with WT gp19 clone. C) Cells with mutant gp19 clone. D) Cells with
gp42 clone. E) Cells with gp43 clone. F) Cells with gp44 clone. (Pictures were taken at
different dates.)
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Effect of Lysogeny on Host Cell Metabolism
High-throughput phenotypic microarray analysis was used to determine if the
lysogeny of M. smeg with MooMoo-T or MooMoo-C (strains RK1421 and RK1422)
alters host cell metabolism. No significant differences in cellular metabolism were
observed (Figure 32A-C). Table 6 illustrates the results between each lysogen and WT
M. smeg.
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Figure 32A-C.
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lysogen
MooMoo-C

Table 6. Phenotypic Microarray data.
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Does gp19 Affect Lysogeny Frequency?
As noted earlier, lysogeny frequencies for MooMoo-C were significantly lower
than MooMoo-T. Since the gp19 clones did not appear to affect phage plating (see
Figure 31B-C), we asked if the lysogeny frequency might be affected. A different class
of mutations that could result in a clear plaque phenotype are those that interfere with the
establishment of lysogeny. Studies with other phages show that a number of genes are
required for this process, but the involvement of a minor tail protein has never been
reported. M. smeg gp19 clones were evaluated for potential changes in the lysogeny
frequencies when the gp19 gene is expressed from the plasmid. Table 7 summarizes the
results. Though there is some slight variation in the frequencies, the results suggest the
gp19 clones from MooMoo-T has a lysogeny frequency that is similar to MooMoo-T
lysogeny of M. smeg host cells that do not carry a plasmid. It is clear that the presence of
cloned copies of WT gp19 from MooMoo-T did not compensate for the low lysogeny
frequency obtained with MooMoo-C phage.
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Table 7. Lysogeny frequencies on M. smeg cells that carry cloned gp19 gene
from MooMoo-T or MooMoo-C
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DISCUSSION

Roughly 80 years has passed since the fist mycobacteriophage was isolated. To
date, over 10,000 mycobacteriophages have been collected and characterized, and over
1700 of these have been completely sequenced (72). The breadth of mycobacteriophage
genomic and morphological diversity has been illuminated by the massive amounts of
accumulated data obtained through programs such as SEA-PHAGES (81, 82). Research
on the methods mycobacteriophages bind, deliver and manipulate their hosts has been
exploited to develop multiple applications, including genome engineering techniques and
therapeutics.

Examples include:

assays that can detect the drug susceptibility of

tuberculosis, vectors capable of introducing deleterious genes into Mycobacterium and
recombineering systems that allow the introduction of point mutations anywhere in the
Mycobacterium genome (44). The therapeutic potential of mycobacteriophages to treat
pathogenic Mycobacteria is also being actively explored.

However, the number of

mycobacteriophages that can cross-infect both non-pathogenic M. smeg, the primary host
used in the SEA-PHAGES program, and pathogenic species of Mycobacterium is small
(44).
In this study, I discovered a clear plaque mutant of a temperate
mycobacteriophage called MooMoo. As previously discussed, temperate phages can
enter either the lytic or lysogenic phage life cycles. The lysis-lysogenic decision is
regulated by the production of the phage repressor protein that blocks early gene
expression by binding to stoperator sites along the genome (44).

Because phage

repressor mutations are a common class of mutations that produce a clear plaque
phenotype, we predicted MooMoo-C had suffered a mutation(s) in its repressor gene.

83

Surprisingly, whole genome sequencing revealed a single base change in a minor tail
protein gene, gp19.

To identify the repressor gene and to verity that it was not

responsible for the observed clear plaque phenotype, several candidate genes whose
products could potentially serve as the phage repressor were predicted using
bioinformatic tools. Each candidate gene was successfully cloned into a shuttle vector
and transformed into E. coli for initial characterization.

After the constructs were

confirmed, the clones were moved into M. smeg where the phenotype could be assessed.
The pLAM-12 shuttle vector used in this study is also an expression vector where cloned
genes are placed under the control of an inducible promoter. This feature allowed us to
determine if overexpression of the cloned gene resulted in an observable phenotype. We
have shown that cells that contain a cloned copy of the gp42 gene, and no other phage
genes, prevented infection of MooMoo-T and MooMoo-C phage.

Based on our

evidence, we conclude that gp42 is the repressor for MooMoo (51).
As mentioned above, whole genome sequencing of bacteriophage MooMoo
revealed that the clear plaque mutant contained a single amino acid substitution in the
minor tail protein gene (gp19). The mutation is located downstream of a D-alanyl-Dalanine-carboxypeptidase domain. Phage carboxypeptidase domains form the largest
class of enzymatic domains specifically targeting different components of the bacterial
cell wall (47). Published data suggests that the D-ala-D-ala-carboxypeptidase motif
assists in phage infection by enzymatically destabilizing the cross-linking covalent bonds
within peptidoglycan (5). We suggest that the native protein conformation of WT gp19
may occlude the catalytic D-ala-D-ala-carboxypeptidase domain except during the
infection process and that the serineproline substitution in the mutant gp19 may alter

84

the conformation and expose the enzymatic domain.

The “exposed domain” could

potentially increase the presumed degradation activity of the tail leading to the cell wall
destabilization and cell lysis. This proposed mechanism explains how a mutation in a tail
protein could influence the plaque phenotype.
Mycobacteriophage tails play a critical role in host cell recognition, attachment
and penetration and are composed of several different proteins (17).

Interestingly,

genomic analysis of siphoviridae mycobacteriophage genomes shows that some of these
genomes contain five to eight minor tail protein genes (17). Experiments with other
phages have shown that binding of phage tail fibers to host cell surface receptors triggers
profound structural changes within the phage, bringing secondary tail structures (i.e. tail
tip) in contact with the cell surface (46). The enzymatic activity in phage tails may
induce host cell lysis without phage production, a phenomenon referred to as “lysis from
without” (80). There is precedence for enzymatic activity in some mycobacteriophage
tails and this activity appears to alter the host cell surface. Mycobacteriophage Bxb1 is a
temperate phage that typically forms turbid plaques with impressively large halos on
lawns of confluent WT M. smeg (45). A clear plaque mutant of Bxb1 also forms halos
that are indistinguishable from the WT phage. However, only the WT, turbid plaque
forming phage could establish lysogeny. Viable phages could be isolated from the halos
formed by their respective phages but these phages did not appear to be produced from
active lytic infections. The genomic analysis of Bxb1 revealed a unique D-ala-D-alacarboxypeptidase domain in the minor tail protein gene (45). This led the authors to
propose that the viable phage particles diffuse through the agar.

The authors also

proposed the enzymatic activity of the tail modify the cell surface of the non-growing
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Mycobacterium cells and alters the appearance of the lawn (e.g. forming a halo; 45).
Other examples of enzymatic activities in phage tails have been described in phages from
various clusters and subclusters (A1, C1, D, E, F, H1 I1, J and singletons Corndog and
Wildcat) where the genomes encoded tail proteins with β-lactamase-like D-ala-D-alacarboxypeptidase activity that is presumed to be associated with the tail tip (17).
Both MooMoo and Bxb1 are temperate mycobacteriophages. MooMoo-T forms
plaques with a halo (noted as “bulls-eye”) and readily lysogenizes WT M. smeg host
cells. Since MooMoo gp19 also contains the D-ala-D-ala motif, we performed the Bxb1
halo experiment using MooMoo-T and MooMoo-C phages. Neither MooMoo-T nor
MooMoo-C showed any evidence of halo expansion (data not shown). Our evidence
suggests that no enzymatic activity, similar to that observed with Bxb1, is associated with
MooMoo phage particles.
Several unique properties of mycobacteriophage MooMoo were characterized in
this study and are summarized here. The analysis of the MooMoo-T and MooMoo-C
phage particles showed that both are morphologically identical (siphoviridae) with
prolate capsids (approx. 113 nm long x 25 nm wide) and long (225 nm), flexible tails.
This analysis proved that the mutation in the minor tail protein of MooMoo-C does not
affect phage morphology.
How the mutation causes the clear plaque phenotype remains unanswered at this
time, but our characterization of MooMoo has identified a number of interesting
properties. MooMoo-T and MooMoo-C can each form stable lysogens and are immune
to both MooMoo-T and MooMoo-C phage superinfection. This information was used to
establish the identity and verify the activity of the phage repressor, gp42. MooMoo-T
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and MooMoo-C have significantly different lysogeny frequencies (MooMoo-T, 83.53%
vs MooMoo-C, 4.21%). It is unclear how a mutation in the minor tail protein gene could
influence lysogeny frequency. However, we did show that the presence of the cloned
copy of WT gp19 did not alter the lysogeny frequency of either MooMoo-T or MooMooC. If gp19 plays a direct role in the observed difference in lysogeny frequencies, we
expected the WT copy to compensate for the apparent lysogeny defect displayed by
MooMoo-C. A trivial explanation for the lack of complementation is that the cloned
copy of gp19 is not expressed. This possibility is explored further below.
Lysogeny can often alter the physiology of the host cell (68, 69, 78). We detected
no changes in host cell physiology when M. smeg is lysogenized with either MooMoo-T
or MooMoo-C. The absence of an observed effect could be due to inherent limitations of
the chosen assay.

A more sensitive assay capable of detecting changes in gene

expression (e.g. RNAseq or DNA microarray) may be a better approach.
The research described in this study has established the foundation for future
work on bacteriophage MooMoo. The next steps in the characterization of this unique
bacteriophage include optimizing the lysis of M. smeg cells so that the expression of the
cloned genes can be verified by SDS-PAGE. I made several unsuccessful attempts to
efficiently lyse M. smeg cells using a number of different procedures. Quantitative
plating of cells after sonication proved the published conditions were ineffective at lysing
M. smeg cells (48, 49, 50). However, the E. coli cells that were tested as a control were
readily lysed and produced consistent banding patterns on SDS-PAGE gels (data not
shown). In the absence of a demonstrable and measureable phenotype, the optimization
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of cell lysis conditions will be necessary to conclusively prove that the plasmid clones do
indeed express the gp19 protein.
Another important experiment would be to delete gp19 from the MooMoo-T
genome to see if its absence affects phage morphology, plaque phenotype and lysogeny
frequency. MooMoo-T and MooMoo-C form distinct and different plaque phenotypes
(turbid and clear, respectively), but the phage particles are morphologically
indistinguishable.

Minor tail genes have important roles in mediating phage tail

assembly. Published reports have shown that mycobacteriophages (e.g. TM4) that suffer
deletions of similar genes have shortened tails (17, 79). I hypothesize that deleting gp19
from mycobacteriophage MooMoo will result in a clear plaque forming phage with a
shortened tail.
Lastly, the mosaic nature of MooMoo’s genome suggests that it acquired genes
from other phages and/or hosts. To gain insight into MooMoo’s evolutionary history, it
would be instructive to determine the host range of mycobacteriophage MooMoo by
plating it on a variety of Actinomycetales hosts (i.e Gordonia spp.). Recent publications
have shown that expanded host range mutants can be recovered and that the responsible
mutations occur in the phage tail proteins (5, 13).
MooMoo is an enigma. Sequenced singleton mycobacteriophages make up less
than 5% of the mycobacteriophage population in the database (72). More singleton
bacteriophages need to isolated and further characterized to expand the genomic richness
within singleton bacteriophage populations. The research described in this study has
provided an important insight into a unique mycobacteriophage and has set the stage for
further exploration.
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APPENDIX I
Medias
A. 7H9 Neat stock (per 900 mLs): 4.7 g DifcoTM Middlebrook 7H9 Broth Base
(Fisher Cat. No. DF0713-17-9), 5 mL of 40% glycerol (Appendix II-A) and Q.S.
with sterile water. The media was aliquotted into bottles (100 mL/bottle) then
autoclaved. 7H9 Neat stock is stored at room temperature.
B. 7H9 Complete without Tween80: 7H9 Neat stock (final concentration 1X; see
above), AD Supplement (final concentration 10%; Appendix II-B), CB (final
concentration 50 μg/mL; Appendix III-A), CHX (final concentration 10 μg/mL;
Appendix III-B), 100 mM CaCl2 (final concentration 1 mM; Appendix II-Ci).
C. 7H9 Complete with Tween80: 7H9 Neat stock (final concentration 1X), AD
Supplement (final concentration 10%), CB (final concentration 50 μg/mL), CHX
(final concentration 10 μg/mL), 100 mM CaCl2 (final concentration 1 mM), 20%
Tween80 (final concentration 0.05%; Appendix II-D).
D. Luria Agar Plate Media supplemented with CB and CHX (per 1 L): 30.5 g
DifcoTM Luria Agar Base, Miller (Fisher Cat. No. DF0413-17-2) and Q.S. with
sterile water. The plate media was autoclaved and then cooled to 60°C. Prior to
pouring, CB and CHX (final concentrations of 50 μg/mL and 10 μg/mL,
respectively) were added. Plates were solidified and then cooled at room
temperature for two days before storing at 4°C.
E. Luria Agar Plate Media supplemented with CB, CHX and Kan (per 1 L): 30.5 g
DifcoTM Luria Agar Base, Miller and Q.S. with sterile water. The plate media
was autoclaved and then cooled to 60°C.
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Prior to pouring, CB (final

concentration of 50 μg/mL), CHX (final concentration of 10 μg/mL) and Kan
(final concentration of 50 μg/mL; Appendix III-C) were added. Plates were
solidified and then cooled at room temperature for two days before storing at 4°C.
F. Luria Agar Plate Media supplemented with CB, CHX, Kan and Acetamide (per
500 mL): 15.3 g DifcoTM Luria Agar Base, Miller, to 493.5 mL with sterile water.
The plate media was autoclaved and then cooled to 60°C. Prior to pouring,
acetamide (final concentration 0.2%; Appendix II-O), CHX, CB and Kan (final
concentrations 10 μg/mL, 50 μg/mL and 50 μg/mL, respectively) were added.
Plates were solidified and then cooled at room temperature for two days before
storing at 4°C.
G. 7H9 Top Agar (per 1 L): 4.7g DifcoTM Middlebrook 7H9 Broth Base, 4 g
DifcoTM Agar, Granulated (Fisher Cat. No. DF0145-17-0), 2.5 mL of 40%
glycerol stock and Q.S. with sterile water. The media was continuously stirred
with heating until a rolling boil was achieved. After which, the media was
removed from heat, but continued stirring. The Top Agar was aliquotted into
media bottles (50 mL/bottle) and then autoclaved. 7H9 Top Agar is stored at
room temperature. Prior to plating, 100 mM CaCl2 is added (final concentration 1
mM).
H. LB Broth (per 1 L): 20 g LB Broth, Lennox (Fisher Cat. No. BP1427-500) and
Q.S. with sterile water.

The media was aliquotted into media bottles (100

mL/bottle) and autoclaved. LB Broth is stored at room temperature.
I. LB Agar Plate Media supplemented with Kan (per 1 L): 20 g LB Broth, Lennox,
15 g DifcoTM Agar, Granulated and Q.S. with sterile water. The plate media was
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autoclaved and then cooled to 60°C. Prior to pouring, Kan (final concentration of
50 μg/mL) was added.

Plates were solidified and then cooled at room

temperature for two days before storing at 4°C.
J. 7H9-ADC (per 200 mL): 7H9 Neat stock (final concentration 1X), CB (final
concentration 50 μg/mL), CHX (final concentration 10 μg/mL), 100 mM CaCl2
(final concentration 1 mM), Kan (final concentration 50 μg/mL).
K. Induction Media (per 200 mL): 7H9 Neat stock (final concentration 1X), CB
(final concentration 50 μg/mL), CHX (final concentration 10 μg/mL), 100 mM
CaCl2 (final concentration 1 mM), Kan (final concentration 50 μg/mL), 20%
Succinic Acid Solution (final concentration 0.2%; Appendix II-P).
L. Super Optimal Broth with Catabolite (SOC) Repression (per 1 L): 20 g Tryptone
(Cat. No.), 5 g Yeast Extract (Cat. No.), 0.5 g Sodium chloride (Fisher Cat. No.
BP358-1), 250 mM KCl (to final concentration of 2.5 mM) and 800 mL of sterile
water. The pH is adjusted to 7 and then autoclaved. After cooling to 60°C, 20%
Glucose (final concentration 20 mM), 1 M MgCl2 (final concentration 10 mM;
Appendix II-R) and 1 M MgSO4 (final concentration 10 mM; Appendix II-G)
were added.
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APPENDIX II
Buffers, Reagents and Stock Solutions
A. 40% Glycerol stock (per 200 mL): 80 mL of Acros Organics Glycerol (Fisher
Cat. No. AC410985000) and Q.S. with sterile water. The solution was transferred
into a media bottle, then autoclaved and stored at room temperature.
i. 10% Glycerol stock (per 1 L): 100 mL of Acros Organics Glycerol and
Q.S. with sterile water. The solution was aliquotted into media bottles (100
mL/bottle) and autoclaved. 10% glycerol is stored at room temperature.
B. AD Supplement stock (per 250 mL): 2.13 g Sodium chloride (Fisher Cat. No.
BP358-1), 5 g Dextrose (D-Glucose) Anhydrous (Fisher Cat. No. D16-500), 12.5
g Alfa Aesar Albumin, Bovine, Cohn Fraction V, 98% Immunoassay grade,
protease and enzyme-free, pH 7.0 (Fisher Cat. No. AAJ6573122) and Q.S. with
sterile water. The solution was filter-sterilized into a sterile media bottle using a
0.2 μm SFCA membrane NalgeneTM Rapid-FlowTM sterile disposable bottle top
filter (Fisher Cat. No. 09-740-22H). AD Supplement is stored at 4°C.
C. 1 M Calcium chloride (CaCl2) stock (per 500 mL): 55.5 g Calcium chloride
(Fisher Cat. No. C77-500) and Q.S. with sterile water.

The solution was

aliquotted into media bottles (100 mL/bottle) and then autoclaved. 1 M CaCl2 is
stored at room temperature.
i. 100 mM CaCl2 stock (per 1 L): 11.1 g CaCl2 and Q.S. with sterile water.
The solution was aliquotted into media bottles (100 mL/bottle) and then
autoclaved. 100 mM CaCl2 is stored at room temperature.
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D. 20% Tween80 stock (per 40 mL): 8 mL TweenTM80 (Fisher Cat. No. BP338-500)
and Q.S. with sterile water. The solution was filter-sterilized into a 50 mL
CorningTM Tube Top 0.22 μm vacuum filter-sterilization unit (Fisher Cat. No. 09761-34). 20% Tween80 is stored at room temperature.
i. 1.2% Tween80 sock (per 500 mL): 6 mL 20% Tween80 stock (see above)
and Q.S. with sterile water. The solution was filter-sterilized into a media
bottle using a 0.2 μm SFCA membrane NalgeneTM Rapid-FlowTM sterile
disposable bottle top filter. 1.2% Tween80 is stored at room temperature.
E. Phage Buffer (PB) stock (per 1 L): 4 g Sodium chloride, 1 M Tris-HCl, pH 7.5
stock (final concentration 10 mM; Appendix II-F), 1 M Magnesium sulfate
(MgSO4) stock (final concentration 10 mM), 100 mM CaCl2 stock (final
concentration 1 mM) and Q.S. with sterile water. The buffer was aliquotted into
media bottles (250 mL/bottle) and then autoclaved.

PB is stored at room

temperature.
F. 1 M Tris-HCl, pH 7.5 stock (per 500 mL):

60.57 g Acros Organics

Tris(hydroxymethyl)aminomethane (Fisher Cat. No. AC167620010), half volume
with sterile water. The pH was adjusted with 12 M Hydrochloric acid (from the
biotech center) prior to bringing the total volume with sterile water. The solution
was transferred into a media bottle and then autoclaved. 1 M Tris-HCl is stored at
room temperature. (NOTE: Several 1M Tris-HCl stock solutions were made at
different pH levels for multiple applications. For this work, four 1 M Tris-HCl
stocks were made as described above at pH levels 7.3, 7.5, 8.0 and 8.2.)
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G. 1 M MgSO4 stock (per 200 mL): 24.07 g Magnesium sulfate anhydrous (Fisher
Cat. No. M65-500) and Q.S. with sterile water. The solution was filter-sterilized
into a media bottle using a 0.2 μm SFCA membrane NalgeneTM Rapid-FlowTM
sterile disposable bottle top filter (Fisher Cat. No. 09-740-22H). 1 M MgSO4 is
stored at room temperature.
i. 10 mM MgSO4 stock (per 50 mL): 0.5 mL of 1 M MgSO4 stock with 49.5
mL sterile water. The solution was filter-sterilized using the CorningTM
Tube Top 0.22 μm vacuum filter-sterilization unit and stored at room
temperature.
H. Nuclease Mix (per 10 mL): 88 mg Sodium chloride was dissolved in 4.25 mL
sterile water (final concentration 150 mM). Aseptically, DNase I stock (final
concentration 250 μg/mL; Appendix II-I), RNase A stock (final concentration 250
μg/mL; Appendix II-J) and glycerol (final concentration 50%) were added to the
solution. After thoroughly mixed, the solution was aliquotted (1 mL/tube) into
Nalgene® System 100TM Cryogenic Tubes (Fisher Cat. No. 5000-1012).
Nuclease Mix is stored at -20°C.
I. DNase I stock (5 mg/mL):

The total of MP BioMedicals DNase I, bovine

pancreases (Fisher Cat. No. ICN10057520) weighed is divided by 5 to determine
the volume of sterile water added. Once in solution, it was filter-sterilized into a
sterile 15 mL tube with the GE Healthcare WhatmanTM Puradisc 0.2 µM syringe
filters, and then aliquotted (1 mL/tube) into Nalgene® System 100TM Cryogenic
Tubes. DNase I is stored at -20°C.
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J. RNase A stock (10 mg/mL): The total of RNase A, bovine pancreases (Fisher
Cat. No. BP2539-1) weighed is divided by 10 to determine the volume of sterile
water added. Once in solution, it was filter-sterilized into a sterile 15 mL tube
with the GE Healthcare WhatmanTM Puradisc 0.2 µM syringe filters, and then
aliquotted (1 mL/tube) into Nalgene® System 100TM Cryogenic Tubes. RNase A
was stored at -20°C.
K. Elution Buffer (EB) solution (per 50 mL): 0.5 mL of 1 M Tris-HCl stock, pH 8.0
(Appendix II-F) with 45.5 mL sterile water. EB is stored at room temperature.
L. Phage Precipitation Solution (per 100 mL): 19.3 g Sodium chloride, 30 g Acros
Organics Poly(ethylene glycol), PEG8000 (Fisher Cat. No. AC418050010) and
Q.S. with sterile water. The solution was filter-sterilized into a media bottle using
a CorningTM Tube Top 0.22 μm vacuum filter-sterilization unit.

Phage

Precipitation Solution is stored at room temperature.
M. PM Additive Solution 1 (per 500 mL): 1 M MgCl2 (final concentration 240 mM),
1 M CaCl2 (final concentration 120 mM; Appendix II-C), 20% Tween80 (final
concentration 1.2%) and Q.S. with sterile water. The solution was filter-sterilized
into a media bottle using a 0.2 μm SFCA membrane NalgeneTM Rapid-FlowTM
sterile disposable bottle top filter. PM Additive Solution 1 is stored at 4°C.
N. PM Additive Solution 2 (per 500 mL): 1 M MgCl2 (final concentration 240 mM),
1 M CaCl2 (final concentration 120 mM), 20% Tween80 (final concentration
1.2%), 1 M Dextrose (D-glucose) stock (final concentration 600 mM; Appendix
II-S) and Q.S. with sterile water. The solution was filter-sterilized into a media
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bottle using a 0.2 μm SFCA membrane NalgeneTM Rapid-FlowTM sterile
disposable bottle top filter. PM Additive Solution 2 is stored at 4°C.
O. 20% Acetamide Solution (per 100 mL): 20 g Acetamide, 99% pure (Fisher Cat.
No. AC153631000) and Q.S. with sterile water. The solution was filter-sterilized
into a media bottle using the CorningTM Tube Top 0.22 μm vacuum filtersterilization unit. 20% Acetamide is stored at room temperature.
P. 20% Succinic Acid Solution (per 100 mL): 20 g Butanedioic acid (succinic acid)
disodium salt hexahydrate (Sigma Cat. No. S-2378) and Q.S. with sterile water.
The solution was filter-sterilized using the ThermoScientificTM NalgeneTM RapidFlowTM 0.2 μm PES membrane sterile disposable filter unit (Fisher Cat. No. 09741-01). 20% Succinic Acid is stored at room temperate.
Q. Mycobacterium Freezing Media (per 100 mL): 43.75 mL 7H9 Neat stock, 5 mL
AD Supplement stock, 1.25 mL 20% Tween80 stock and Q.S. with 100%
glycerol.

The media was filter-sterilized into two 50 mL tubes using the

CorningTM Tube Top 0.22 μm vacuum filter-sterilization unit. Mycobacterium
Freezing Media is stored at 4°C.
R. 1 M Magnesium chloride (MgCl2) stock (per 100 mL): 20.33 g Magnesium
chloride hexahydrate (Fisher Cat. No. M33-500) and Q.S. with sterile water. The
solution was filter-sterilized into a media bottle using a 0.2 μm SFCA membrane
NalgeneTM Rapid-FlowTM sterile disposable bottle top filter. 1 M MgCl2 is stored
at room temperature.
S. 1 M Dextrose (D-glucose) stock (per 50 mL): 9.01 g Dextrose (D-glucose)
anhydrous (Fisher Cat. No. D16-500) and Q.S. with sterile water. The solution
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was filter-sterilized into a 50 mL tube using the CorningTM Tube Top 0.22 μm
vacuum filter-sterilization unit. 1 M Dextrose is stored at room temperature.
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APPENDIX III
Antibiotics, Antimycotics and Cytotoxic Agents
A. Carbenicillin (CB) stock (50 mg/mL): The total of Carbenicillin, Disodium salt
(Fisher Cat. No. BP26485) weighed is divided by 50 to determine the volume of
sterile water added. Once in solution, it was filter-sterilized into a sterile 15 mL
tube using a GE Healthcare WhatmanTM Puradisc 0.2 µM syringe filter.
Carbenicillin is stored at 4°C.
B. Cycloheximide (CHX) stock (10 mg/mL):

The total of Arcos Organics

Cycloheximide (Fisher Cat. No. AC357420050) weighed is divided by 10 to
determine the volume of sterile water added. Once in solution, it was filtersterilized into a sterile 15 mL tube using a GE Healthcare WhatmanTM Puradisc
0.2 µM syringe filter. Cycloheximide is stored at 4°C.
C. Kanamycin (Kan) stock (50 mg/mL): The total of MP Biomedicals Kanamycin
Monosulfate (Fisher Cat. No. ICN15002901) weighed is divided by 50 to
determine the volume of sterile water added. Once in solution, it was filtersterilized into a sterile 15 mL tube using a GE Healthcare WhatmanTM Puradisc
0.2 µM syringe filter and then aliquotted (1 mL/tube) into Nalgene® System
100TM Cryogenic Tubes. Kanamycin is stored at -20°C.
D. Mitomycin C stock (2 mg/mL): 2 mL of a 1:1 solution of ethanol to sterile water
solution was prepared and injected through the seal of the Mitomycin C (Fisher
Cat. No. BP2531-2) bottle. The solution was transferred into a Nalgene® System
100TM Cryogenic Tube covered with aluminum foil. Mitomycin C is stored at
4°C.
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